Joint Commission Monograph aims to decrease Central Line Associated Bloodstream infections (CLABSIs)
States News Service; May 16, 2012
The Joint Commission, in collaboration with Joint Commission Resources (JCR) and Joint Commission International (JCI), developed a new monograph containing the most current information, evidence-based guidance and resources to help health care organizations reduce the current risks and resulting harm associated with CLABSI. JCR and JCI are not-for-profit affiliates of The Joint Commission. The monograph was produced in partnership with hospital infections prevention leaders from the Society for Hospital Epidemiology of America (SHEA), the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC), the National Institutes of Health (NIH), the Infectious Diseases Society of America (IDSA), the Association for Vascular Access (AVA), and the International Nosocomial Infection Control Consortium (INICC).
Central line-associated bloodstream infections (CLABSIs) are a serious form of health care-associated infections (HAIs), with a mortality rate of 12 to 25 percent in the United States alone. Reliable access to the bloodstream is one of the most essential components of modern medical care, but bloodstream access medical devices introduce a risk of bloodstream infection (BSI). The device that poses the greatest risk for BSI is the central venous catheter (CVC), also known as a central line. It is estimated that more than 5 million CVCs are inserted each year; any patient with a central line is at risk of developing a CLABSI, which is associated with increased morbidity, mortality and cost. The U.S. Centers for Disease Control and Prevention recently estimated the annual cost of CLABSI is more than $1 billion, and the estimated cost per patient is more than $16,000. The risk associated with CLABSI is even greater in developing countries, where the rates of HAIs related to devices are, in most cases, three to five times greater.
Recent patient safety initiatives have demonstrated how preventable CLABSIs can be when evidence-based guidelines are consistently put into practice at the bedside. The project focuses on the identification and broad dissemination of preferred practices and technological solutions to prevent CLABSI. Phase one of the project is the publication of the monograph, which highlights evidence-based practices known to help prevent CLABSI. Phase two of the project will use this valuable information to develop a toolkit designed to support organizations as they seek to reduce CLABSI rates. It will include evidence- and expert-based interventions, guidelines and resources to address CLABSI.
- May 16, 2012
- Posted by Jamie







